



Media Releases » **Torrent Pharma announces Q3 FY 2015-16 results. Declares interim Dividend of 400% (Rs 20 per share)**

February 4th, 2016

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 31st December, 2015.

Financial Highlights	Q3 FY 15-16	Q3 FY 14-15	QoQ Growth	YTD FY 15-16	YTD FY 14-15	YTD Growth
Revenue	1,539	1,168	32%	5,177	3,499	48%
EBITDA	663	302	120%	2,476	1,022	142%
PAT	483	167	189%	1,500	621	142%
EPS	20.3	8.2	146%	84.7	36.7	130%

Quarterly Financials

- For Q3 FY 2015-16 revenues were at Rs. 1,539 crores up by 32% from Rs. 1,168 crores during the same period last year
- EBITDA for Q3 FY 2015-16 was at Rs. 663 crores up by 120% from Rs. 302 crores during the same period last year

302 crores during the same period last year

- PAT for Q3 2015-16 was at Rs. 483 crores up by 189% from Rs.167 crores during the same period last year

Q3 PERFORMANCE HIGHLIGHTS

BRANDED GENERICS

India Business

- Domestic formulation business recorded revenues of Rs. 446 crores for Q3 FY 2015-16 showing 7% growth. Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term
- As per AIOCD, the domestic formulation business growth was 9% compared to covered market growth of 14% for Q3 FY 2015-16.(AIOCD Dataset Dec 2015)

Brazil Business

- Brazilian business recorded revenues of Rs. 118 crores vs Rs. 156 crores showing 25% de-growth. The de-growth in quarter is due to currency movements and realignment of channel inventory
- As per IMS data , the growth is 24% compared to covered market growth of 20%, in value terms. (IMS dataset Dec 2015)

GENERICS

USA

- Revenues from US operations for Q3 FY 2015-16 registered growth of 226%

YTD Financials

- For YTD FY 2015-16 revenues were at Rs. 5,177 crores up by 48% from Rs. 3,499 crores during the same period last year
- EBITDA for YTD FY 2015-16 was at Rs. 2,476 crores up by 142% from Rs. 1,022 crores during the same period last year
- PAT for YTD 2015-16 was at Rs. 1,500 crores up by 142% from Rs.621 crores during the same period last year
- Exceptional Items during the period represents write back of provision for diminution in value of investments of Rs. 37 crores and profit on sale of investments of Rs. 16 crores

YTD PERFORMANCE HIGHLIGHTS

BRANDED GENERICS

India Business

- Domestic formulation business recorded revenues of Rs.1,377 crores for YTD FY 2015-16 showing 14% growth
- As per AIOCD, the domestic formulation business growth was 20% compared to covered market growth of 14% for MAT FY 2015-16. (AIOCD Dataset Dec 2015)

Brazil Business

- Brazilian business recorded revenues of Rs. 387 crores vs Rs. 465 crores showing 17% de-growth. Adjusted for currency movements growth is 15%
- As per IMS data , the growth is 28% compared to covered market growth of 20%, in value terms. (IMS data set Dec 2015)

GENERICS**USA**

- Revenues from US operations for YTD FY 2015-16 registered growth of 255%. Current quarter and YTD has continued benefit of high sales of our largest product. However, base sales also recorded exceptional growth with support of new launches Esomeprazole and generic Detrol

About Torrent Pharma

Torrent Pharma, with annual revenues of almost Rs. 4700 crores is the flagship Company of the Torrent Group. Torrent continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset).

Torrent has a full equipped Research Center, employing almost 600 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.